US FDA Advisory Committee Open Public Hearing Changes Urged
Executive Summary
Patients want more attention paid to their experiences with an investigational drug, while consumer groups and academics say those who were harmed also should be heard.
Topics
- Subjects
- Advisory Committees
- FDA
- Regulation
- Industries
- BioPharmaceutical
- Regions
- North America
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PS154880
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
PS154880
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.